|
95
|
349
|
5omhA |
P38alpha in complex with pyrazolobenzothiazine inhibitor coxh11 |
|
109
|
347
|
6qagA |
Erk2 mini-fragment binding |
|
106
|
347
|
6qawA |
Erk2 mini-fragment binding |
|
109
|
350
|
6q7kA |
Erk2 mini-fragment binding |
|
115
|
347
|
6qaqA |
Erk2 mini-fragment binding |
|
106
|
347
|
6qalA |
Erk2 mini-fragment binding |
|
115
|
348
|
6m95A |
Structure-based design, synthesis, and biological evaluation of imidazo[4,5-b]pyridine-2-one based p38 map kinase inhibitors by scaffold hopping: compound 1 |
|
101
|
348
|
6m9lA |
Structure-based design, synthesis, and biological evaluation of imidazo[4,5-b]pyridine-2-one based p38 map kinase inhibitors by scaffold hopping - compound 10 |
|
94
|
364
|
6dtlA |
Mitogen-activated protein kinase 6 |
|
106
|
346
|
6fxvA |
Crystal structure of erk2 in complex with an adenosine derivative |
|
114
|
348
|
6hwvA |
Crystal structure of p38alpha in complex with a photoswitchable 2-azoimidazol-based inhibitor (compound 3) |
|
112
|
348
|
6hwtA |
Crystal structure of p38alpha in complex with a reduced photoswitchable 2-azothiazol-based inhibitor (compound 31) |
|
113
|
349
|
6hwuA |
Crystal structure of p38alpha in complex with a photoswitchable 2-azothiazol-based inhibitor (compound 2) |
|
129
|
408
|
5z33A |
Crystal structure of mitogen-activated protein kinase mps1 in magnaporthe oryzae |
|
107
|
357
|
3sa0A |
Complex of erk2 with norathyriol |
|
109
|
345
|
5nhvA |
Human erk2 with an erk1/2 inhibitor |
|
110
|
345
|
5nhlA |
Human erk2 with an erk1/2 inhibitor |
|
116
|
348
|
5nhhA |
Human erk2 with an erk1/2 inhibitor |
|
109
|
348
|
5mtxA |
Dibenzooxepinone inhibitor 12b in complex with p38 mapk |
|
104
|
349
|
5n63A |
Crystal structure of p38alpha in complex with lipid pocket ligand 9c |
|
111
|
350
|
5mz3A |
P38 alpha mutant c162s in complex with cmpd2 [n-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide] |
|
114
|
348
|
5n65A |
Crystal structure of p38alpha in complex with lipid pocket ligand 9h |
|
108
|
350
|
5n64A |
Crystal structure of p38alpha in complex with lipid pocket ligand 9g |
|
112
|
347
|
5lcjA |
In-gel activity-based protein profiling of a clickable covalent erk 1/2 inhibitor |
|
116
|
350
|
5k4iA |
Crystal structure of erk2 in complex with compound 22 |
|
117
|
347
|
5hd4A |
Dissecting therapeutic resistance to erk inhibition rat wild type sch772984 in complex with (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5-yl]pyrrolidine-3-carboxamide |
|
107
|
348
|
6gdqA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
107
|
347
|
6g9kA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
108
|
347
|
6ge0A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
104
|
347
|
6g8xA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
110
|
347
|
6g93A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
115
|
346
|
6g9mA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
109
|
350
|
6g9aA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
111
|
347
|
6g9nA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
110
|
350
|
6g91A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
105
|
350
|
6g9jA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
111
|
347
|
6g97A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
113
|
350
|
6g92A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
108
|
350
|
6g9dA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
102
|
349
|
6gdmA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
110
|
347
|
6g9hA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
|
101
|
356
|
6f5eB |
Crystal structure of darpin-darpin rigid fusion, variant dd_d12_10_47 in complex jnk1a1 and jip1 peptide |
|
114
|
355
|
6eq9A |
Crystal structure of jnk3 in complex with amp-pcp |
|
114
|
355
|
6emhA |
Crystal structure of jnk3 in complex with a pyridinylimidazole inhibitor |
|
98
|
355
|
6ekdA |
Crystal structure of jnk3 in complex with a pyridinylimidazole inhibitor |
|
108
|
339
|
6dcgA |
Discovery of mk-8353: an orally bioavailable dual mechanism erk inhibitor for oncology |
|
108
|
340
|
6cpwA |
Discovery of 3(s)-thiomethyl pyrrolidine erk inhibitors for oncology |
|
110
|
349
|
6anlA |
Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 map kinase inhibitors |
|
108
|
350
|
5xyxA |
The structure of p38 alpha in complex with a triazol inhibitor |
|
108
|
350
|
5xyyA |
The structure of p38 alpha in complex with a triazol inhibitor |
